0000882104-20-000200.txt : 20201208 0000882104-20-000200.hdr.sgml : 20201208 20201208160731 ACCESSION NUMBER: 0000882104-20-000200 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20201204 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201208 DATE AS OF CHANGE: 20201208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 201375387 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 pdli-20201204.htm 8-K pdli-20201204
false000088210400008821042020-12-042020-12-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 4, 2020

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)
Delaware94-3023969
(State or Other Jurisdiction of Incorporation)(I.R.S. Employer Identification No.)

932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per sharePDLIThe NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨



Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On December 8, 2020, PDL BioPharma, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market, Inc. that the Company intends to voluntarily delist its common stock, par value $0.01 per share (the “Common Stock”), from the Nasdaq Global Stock Market (“Nasdaq”) in connection with the Company’s previously disclosed voluntary Plan of Dissolution. The Company expects to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about December 28, 2020 to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the delisting will be effective on or about January 7, 2021 – ten days after the filing of the Form 25. In connection with the foregoing, the Company requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on December 31, 2020. The Company also announced that, following the effectiveness of the delisting, it intends to file a Form 15 with the SEC to terminate the registration of the Common Stock under Section 12(g) of the Exchange Act, thereby suspending the Company’s Exchange Act reporting obligations.

A copy of the press release announcing the matters summarized above is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 4, 2020, the Company was informed that, effective December 31, 2020, David W. Gryska will resign from his position as a member of the Board of Directors of the Company, including each committee of the Board on which he served. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PDL BIOPHARMA, INC.
(Company)
By:/s/ Dominique Monnet
Dominique Monnet
President and Chief Executive Officer


Dated: December 8, 2020



Exhibit Index



Exhibit No.Description
99.1
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

 EX-99.1 2 a202012088-kex991.htm PRESS RELEASE Document

Exhibit 99.1


image1a.jpg

Contact:
Jody Cain
LHA Investor Relations
310-691-7100
jcain@lhai.com
PDL Announces Timeline for Voluntarily Delisting from Nasdaq

Expects to File a Certificate of Dissolution on January 4, 2021

Trading in PDL’s Common Stock on Nasdaq to be Suspended Prior to Market Opening on December 31, 2020

INCLINE VILLAGE, Nev. (December 8, 2020) - PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company’s common stock from the Nasdaq Global Select Market (“Nasdaq”). PDL expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) and Nasdaq relating to the voluntary delisting of its common stock on or about December 28, 2020 and to suspend trading of its common stock on the Nasdaq Global Select Market prior to the opening of trading on December 31, 2020. PDL does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. PDL intends to file a certificate of dissolution with the Delaware Secretary of State on or about January 4, 2021 and close its stock transfer books at the close of business on this date. The official delisting of PDL’s common stock will be effective on or about January 7, 2021 – 10 days after the filing of the Form 25.

PDL also intends to file a Form 15 with the SEC as soon as practicable following the effectiveness of the delisting to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, as amended. The suspension of PDL’s reporting obligations, including the obligation to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, will be effective upon filing the Form 15. PDL does however intend to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 in March 2021.

The voluntary delisting and deregistration are part of PDL’s previously announced voluntary Plan of Dissolution that was approved by the Board of Directors in February 2020 and at the Annual Meeting of the Company’s stockholders on August 19, 2020. The Company’s Board of Directors considered a number of factors in determining to delist and deregister PDL’s common stock, including the costs and expenses associated with being a publicly traded company, the auditing, legal and other costs associated with continuing to make SEC filings, and the burdens placed on Company management to comply with the


continued listing and reporting requirements, all in light of the Company’s planned dissolution and liquidation.

About PDL Biopharma, Inc.
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies. PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases. In 2006, the Company changed its name to PDL BioPharma, Inc.

On August 19, 2020, PDL announced at the Company's 2020 Annual Meeting of Stockholders approval by stockholders for a Plan of Dissolution authorizing the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution. At its November 5, 2020 meeting, the Board resolved that the Certificate of Dissolution will be filed on January 4, 2021.

For more information please visit https://www.pdl.com/

NOTE: PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein.

Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company's Plan of Dissolution, dissolution, wind-down of operations and the delisting and deregistration of the Company’s common stock. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company’s assets and business, including the implementation or success of the Company's monetization strategy/Plan of Dissolution, are disclosed in the risk factors contained in the Company’s Annual Report on Form 10-K, filed with the SEC on March 11, 2020, in the Company's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2020, August 10, 2020 and November 13, 2020 and in the Company's Definitive Proxy Statement on Schedule 14A filed with the SEC on July 7, 2020. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.



 EX-101.SCH 3 pdli-20201204.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 pdli-20201204_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 pdli-20201204_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 pdli-20201204_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 pdli-20201204_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image1a.jpg LOGO begin 644 image1a.jpg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end XML 9 pdli-20201204_htm.xml IDEA: XBRL DOCUMENT 0000882104 2020-12-04 2020-12-04 false 0000882104 8-K 2020-12-04 PDL BioPharma, Inc. 000-19756 DE 94-3023969 932 Southwood Boulevard Incline Village, NV 89451 775 832-8500 false false false false Common stock, par value $0.01 per share PDLI NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.2
COVER
Dec. 04, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 04, 2020
Entity Registrant Name PDL BioPharma, Inc.
Entity File Number 000-19756
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3023969
Entity Address, Address Line One 932 Southwood Boulevard
Entity Address, City or Town Incline Village,
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89451
City Area Code 775
Local Phone Number 832-8500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol PDLI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000882104
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - COVER Sheet http://ww.pdl.com/role/COVER COVER Cover 1 false false All Reports Book All Reports pdli-20201204.htm a202012088-kex991.htm pdli-20201204.xsd pdli-20201204_cal.xml pdli-20201204_def.xml pdli-20201204_lab.xml pdli-20201204_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pdli-20201204.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "pdli-20201204_cal.xml" ] }, "definitionLink": { "local": [ "pdli-20201204_def.xml" ] }, "inline": { "local": [ "pdli-20201204.htm" ] }, "labelLink": { "local": [ "pdli-20201204_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "pdli-20201204_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "pdli-20201204.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pdli", "nsuri": "http://ww.pdl.com/20201204", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pdli-20201204.htm", "contextRef": "ibebb8884a8a743f780e1c64322e16e63_D20201204-20201204", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - COVER", "role": "http://ww.pdl.com/role/COVER", "shortName": "COVER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pdli-20201204.htm", "contextRef": "ibebb8884a8a743f780e1c64322e16e63_D20201204-20201204", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://ww.pdl.com/role/COVER" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000882104-20-000200-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000882104-20-000200-xbrl.zip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end